Biodexa Pharmaceuticals (STU:5MP2) Total Operating Expense: €5.43 Mil (TTM As of Dec. 2025)


STU:5MP2 Biodexa Pharmaceuticals PLC STU:5MP2
10 GF Score
Price €110,400.00
GF Value €95,593.41
View Full Analysis

What is Biodexa Pharmaceuticals Total Operating Expense?

Biodexa Pharmaceuticals STU:5MP2 10 Total Operating Expense is €5.43 Mil as of Dec. 2025. GuruFocus rates STU:5MP2 with a GF Score™ of 10/100 and a GF Value™ of €95,593.41.

Biodexa Pharmaceuticals's Total Operating Expense for the six months ended in Dec. 2025 was €2.67 Mil. Biodexa Pharmaceuticals's Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was €5.43 Mil.

Biodexa Pharmaceuticals Total Operating Expense Related Terms

Biodexa Pharmaceuticals Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Biodexa Pharmaceuticals's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biodexa Pharmaceuticals Total Operating Expense Chart

Biodexa Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.44 5.20 5.02 4.54 5.36

Biodexa Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.36 2.40 2.09 2.77 2.67
STU:5MP2
10GF Score
Biodexa Pharmaceuticals PLC STU:5MP2
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biodexa Pharmaceuticals Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €5.43 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €5.43 Mil mean?
Biodexa Pharmaceuticals (STU:5MP2) has a Total Operating Expense of €5.43 Mil as of Dec. 2025. Total operating expense is the primary recurring expense associated with central operations. View historical data on Biodexa Pharmaceuticals and its competitors.
Is Biodexa Pharmaceuticals' Total Operating Expense too high?
Biodexa Pharmaceuticals' current Total Operating Expense is €5.43 Mil. Overall, Biodexa Pharmaceuticals has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Biodexa Pharmaceuticals' Total Operating Expense compare to CASIF and OGEN?
Biodexa Pharmaceuticals' Total Operating Expense of €5.43 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Biodexa Pharmaceuticals and its competitors. Biodexa Pharmaceuticals's current Total Operating Expense is €5.43 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biodexa Pharmaceuticals stock overvalued right now?
Biodexa Pharmaceuticals (STU:5MP2) has a current Total Operating Expense of €5.43 Mil. The stock's GF Value™ is €95,593.41, compared to a current price of €110,400.00 — trading 15.5% above its estimated fair value. The current Total Operating Expense is €5.43 Mil. Biodexa Pharmaceuticals' overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Biodexa Pharmaceuticals (STU:5MP2), the current Total Operating Expense is €5.43 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biodexa Pharmaceuticals (STU:5MP2) Overvalued in 2026?

Based on GuruFocus' analysis, Biodexa Pharmaceuticals stock appears to be overvalued. The current stock price of €110,400.00 is trading 15.5% above its estimated GF Value™ of €95,593.41.

Key valuation signals for STU:5MP2:

  • Total Operating Expense: €5.43 Mil
  • GF Value™: €95,593.41 vs. price of €110,400.00 (15.5% above fair value)
  • GF Score™: 10/100

No single metric tells the full story. See the STU:5MP2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biodexa Pharmaceuticals Business Description

Other Exchanges BDRX:USA
Address 1 Caspian Point, Caspian Way, Cardiff, GBR, CF10 4DQ
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
10GF Score

Get the complete analysis for STU:5MP2

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€110,400.00
Price
€95,593.41
GF Value